ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Joseph C BakerVictoria L Seewaldt

Abstract

Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention. Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls. We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with control women. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention. Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.

References

Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Jul 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·M L VeiglS D Markowitz
Sep 10, 1998·Journal of the National Cancer Institute·T E RohanR A Kandel
May 20, 2000·Journal of Mammary Gland Biology and Neoplasia·E AndersonA Howell
Nov 25, 2000·Breast Cancer : the Journal of the Japanese Breast Cancer Society·M HoriM Itabashi
May 16, 2002·Journal of the National Cancer Institute·Lanlan ShenJean-Pierre J Issa
Sep 6, 2002·Oncogene·C Marcelo AldazDaniel Medina
Mar 6, 2003·Journal of the National Cancer Institute·C Kent OsborneRachel Schiff
Nov 25, 2003·The New England Journal of Medicine·James G Herman, Stephen B Baylin
Dec 5, 2003·Journal of the National Cancer Institute·Levy KopelovichJudith R Fay
Apr 15, 2004·Journal of Mammary Gland Biology and Neoplasia·Elizabeth Anderson, Robert B Clarke
May 26, 2004·The Journal of Pharmacology and Experimental Therapeutics·Zeruesenay DestaDavid A Flockhart
Aug 4, 2004·Clinical Pharmacology and Therapeutics·Sebastian RaimundoUlrich M Zanger
Apr 13, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Gregory R BeanVictoria L Seewaldt
Jun 30, 2005·International Journal of Cancer. Journal International Du Cancer·Ji-Ching LaiHuei Lee
Nov 11, 2005·Breast Cancer Research : BCR·Pia P Wegman, Sten Wingren
Oct 13, 2006·The New England Journal of Medicine·Gregory R BeanVictoria L Seewaldt
Nov 23, 2006·Breast Cancer Research and Treatment·Matthew P GoetzJames N Ingle
Jan 16, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Gregory R BeanVictoria L Seewaldt
May 18, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Vanessa K GoldenbergIsaac M Lipkus

❮ Previous
Next ❯

Citations

Mar 5, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Shauna N VasilatosVictoria L Seewaldt
Apr 23, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Catherine Ibarra-DrendallVictoria L Seewaldt
May 20, 2009·Annals of Surgical Oncology·Frank A Orlando, Kevin D Brown
Oct 4, 2013·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Dawei BuDavid Euhus

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Gregory R BeanVictoria L Seewaldt
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Gregory R BeanVictoria L Seewaldt
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Gregory R BeanVictoria L Seewaldt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
C J Fabian
© 2022 Meta ULC. All rights reserved